Evidence map›Paper›PMID 37452418›Full record

Trial reportBMC urology2023

Establishment and validation of serum lipid-based nomogram for predicting the risk of prostate cancer.

Fu Feng, Yu-Xiang Zhong, Yang Chen, Fu-Xiang Lin, Jian-Hua Huang, Yuan Mai, Peng-Peng Zhao, Wei Wei, Hua-Cai Zhu, Zhan-Ping Xu

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Fu Feng *Department of Urinary Surgery, Foshan Hospital of Traditional Chinese Medicine, No.6, Qinren Road, Foshan, 528099, P.R. China.
Yu-Xiang Zhong *Department of Urinary Surgery, Foshan Hospital of Traditional Chinese Medicine, No.6, Qinren Road, Foshan, 528099, P.R. China.
Yang Chen *Department of Urinary Surgery, Foshan Hospital of Traditional Chinese Medicine, No.6, Qinren Road, Foshan, 528099, P.R. China.
Fu-Xiang LinDepartment of Urinary Surgery, Foshan Hospital of Traditional Chinese Medicine, No.6, Qinren Road, Foshan, 528099, P.R. China.
Jian-Hua HuangDepartment of Urinary Surgery, Foshan Hospital of Traditional Chinese Medicine, No.6, Qinren Road, Foshan, 528099, P.R. China.
Yuan MaiDepartment of Urinary Surgery, Foshan Hospital of Traditional Chinese Medicine, No.6, Qinren Road, Foshan, 528099, P.R. China.
Peng-Peng ZhaoDepartment of Urinary Surgery, Foshan Hospital of Traditional Chinese Medicine, No.6, Qinren Road, Foshan, 528099, P.R. China.
Wei WeiDepartment of Urinary Surgery, Foshan Hospital of Traditional Chinese Medicine, No.6, Qinren Road, Foshan, 528099, P.R. China.
Hua-Cai ZhuDepartment of Urinary Surgery, Foshan Hospital of Traditional Chinese Medicine, No.6, Qinren Road, Foshan, 528099, P.R. China.
Zhan-Ping XuDepartment of Urinary Surgery, Foshan Hospital of Traditional Chinese Medicine, No.6, Qinren Road, Foshan, 528099, P.R. China. zcr0601@163.com.
Foshan Hospital of TCM · CNGuangzhou University of Chinese Medicine · CN

Funding

Clinical Drug Research Foundation of Guangdong Province (Special Fund for Orthopedics Analgesia in Surgical Pharmacy) 2021ZT13Foshan "14th Five-Year" Medical Cultivation Key Specialties Construction Project FSPY145003
6 · The paper itself

Abstract

backgroundThis study aimed to explore the value of combined serum lipids with clinical symptoms to diagnose prostate cancer (PCa), and to develop and validate a Nomogram and prediction model to better select patients at risk of PCa for prostate biopsy.

methodsRetrospective analysis of 548 patients who underwent prostate biopsies as a result of high serum prostate-specific antigen (PSA) levels or irregular digital rectal examinations (DRE) was conducted. The enrolled patients were randomly assigned to the training groups (n = 384, 70%) and validation groups (n = 164, 30%). To identify independent variables for PCa, serum lipids (TC, TG, HDL, LDL, apoA-1, and apoB) were taken into account in the multivariable logistic regression analyses of the training group, and established predictive models. After that, we evaluated prediction models with clinical markers using decision curves and the area under the curve (AUC). Based on training group data, a Nomogram was developed to predict PCa.

results210 (54.70%) of the patients in the training group were diagnosed with PCa. Multivariate regression analysis showed that total PSA, f/tPSA, PSA density (PSAD), TG, LDL, DRE, and TRUS were independent risk predictors of PCa. A prediction model utilizing a Nomogram was constructed with a cut-off value of 0.502. The training and validation groups achieved area under the curve (AUC) values of 0.846 and 0.814 respectively. According to the decision curve analysis (DCA), the prediction model yielded optimal overall net benefits in both the training and validation groups, which is better than the optimal net benefit of PSA alone. After comparing our developed prediction model with two domestic models and PCPT-RC, we found that our prediction model exhibited significantly superior predictive performance. Furthermore, in comparison with clinical indicators, our Nomogram's ability to predict prostate cancer showed good estimation, suggesting its potential as a reliable tool for prognostication.

conclusionsThe prediction model and Nomogram, which utilize both blood lipid levels and clinical signs, demonstrated improved accuracy in predicting the risk of prostate cancer, and consequently can guide the selection of appropriate diagnostic strategies for each patient in a more personalized manner.

Indexed as

NomogramsProstatic NeoplasmsBiopsyHumansMaleProstate-Specific AntigenRetrospective StudiesRisk FactorsProstate-Specific AntigenLDL cholesterolNomogramsProstate cancerSerum lipidTriglyceride

Identifiers

PMID37452418
PMCPMC10349516
OpenAlexW4384296815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.